Copenhagen, Denmark – June 6, 2018: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win technology, today announced the appointment of Kathleen Sereda Glaub, MBA, as member of the Board of Directors.
